| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/SLA.0B013E31827E9289 |
| P698 | PubMed publication ID | 23299520 |
| P50 | author | Diane Goere | Q40350292 |
| Valérie Boige | Q41786186 | ||
| Léon Maggiori | Q43312274 | ||
| P2093 | author name string | Dominique Elias | |
| Michel Ducreux | |||
| David Malka | |||
| Frédéric Dumont | |||
| Clarisse Eveno | |||
| Dimitri Tzanis | |||
| Vinicius Gava | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | peritoneal carcinomatosis | Q2071182 |
| chemotherapy | Q974135 | ||
| P304 | page(s) | 1065-1071 | |
| P577 | publication date | 2013-06-01 | |
| P1433 | published in | Annals of Surgery | Q4767866 |
| P1476 | title | Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? | |
| P478 | volume | 257 |
| Q39474649 | A new policy regarding ovarian resection in young women treated for peritoneal carcinomatosis |
| Q55375912 | Adenocarcinoma of the Colon Disguised as Abdominal Wall Abscess: Case Report and Review of the Literature. |
| Q38246361 | Challenges in the multidisciplinary management of stage IV colon and rectal cancer. |
| Q92462064 | Chasing Rainbows? the Possibility of "Cure" in Patients with Colorectal Peritoneal Metastases Undergoing Cytoreductive Surgery and HIPEC-a Retrospective Study by INDEPSO |
| Q92323504 | Colorectal peritoneal metastases: Optimal management review |
| Q92311857 | Comparison of implantation sites for the development of peritoneal metastasis in a colorectal cancer mouse model using non-invasive bioluminescence imaging |
| Q48645092 | Complete cytoreductive surgery plus HIPEC for peritoneal metastases from unusual cancer sites of origin: results from a worldwide analysis issue of the Peritoneal Surface Oncology Group International (PSOGI). |
| Q92504802 | Complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases: results of a propensity score matching analysis from France |
| Q36762307 | Computerized System for Staging Peritoneal Surface Malignancies |
| Q90135126 | Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy With Mitomycin C Used for Colorectal Peritoneal Carcinomatosis |
| Q49545021 | Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for the Elderly: Is It Reasonable? A Meta-Analysis |
| Q36758936 | Cytoreductive Surgery plus HIPEC for Peritoneal Metastases from Colorectal Cancer |
| Q35234968 | Cytoreductive surgery of colorectal peritoneal metastases: outcomes after complete cytoreductive surgery and systemic chemotherapy only |
| Q40399436 | Defining the Chance of Statistical Cure Among Patients with Extrahepatic Biliary Tract Cancer |
| Q36091164 | Detection methods and clinical significance of free peritoneal tumor cells found during colorectal cancer surgery |
| Q55385444 | Diagnostic value of whole-body MRI with diffusion-weighted sequence for detection of peritoneal metastases in colorectal malignancy. |
| Q40384786 | Digital Glissonectomy: A Safe Perihepatic Peritonectomy. |
| Q89814530 | Evaluation of repeat cytoreductive surgery and heated intraperitoneal chemotherapy for patients with recurrent peritoneal carcinomatosis from appendiceal and colorectal cancers: a multicentre Canadian study |
| Q44408342 | Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study. |
| Q28077394 | Hyperthermic Intraperitoneal Chemotherapy and Cytoreductive Surgery in the Management of Peritoneal Carcinomatosis |
| Q92404956 | Impact of Synchronous Versus Metachronous Onset of Colorectal Peritoneal Metastases on Survival Outcomes After Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Multicenter, Retrospective, Observational Study |
| Q35085327 | Impact of distal pancreatectomy on outcomes of peritoneal surface disease treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy |
| Q90599804 | Individualized multimodal treatment strategy for metastatic rectal adenocarcinoma: Case report |
| Q39014341 | Intraperitoneal chemotherapy and cytoreductive surgery for peritoneal metastases coupled with curative treatment of colorectal liver metastases: an updated systematic review |
| Q41715552 | Linear Relationship of Peritoneal Cancer Index and Survival in Patients with Peritoneal Metastases from Colorectal Cancer |
| Q53194818 | Long-Term Survival Benefit and Potential for Cure after R1 Resection for Colorectal Liver Metastases. |
| Q37571642 | Multidisciplinary Treatment for Colorectal Peritoneal Metastases: Review of the Literature |
| Q48179612 | Ninety-day post-operative morbidity and mortality using the National Cancer Institute's common terminology criteria for adverse events better describe post-operative outcome after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy |
| Q37670381 | Obesity and peritoneal surface disease: outcomes after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for appendiceal and colon primary tumors |
| Q91671852 | Outcome of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Colorectal Cancer |
| Q39140018 | Oxaliplatin and molecular-targeted drug therapies improved the overall survival in colorectal cancer patients with synchronous peritoneal carcinomatosis undergoing incomplete cytoreductive surgery |
| Q39465411 | Palliative surgery for colorectal cancer with peritoneal metastasis: a propensity-score matching analysis. |
| Q38199370 | Pathological response to neoadjuvant chemotherapy: a new prognosis tool for the curative management of peritoneal colorectal carcinomatosis. |
| Q39442876 | Patient selection for cytoreductive surgery and HIPEC for the treatment of peritoneal metastases from colorectal cancer |
| Q53213677 | Patients with Peritoneal Carcinomatosis from Gastric Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is Cure a Possibility? |
| Q64087322 | Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parralel-group, phase II-III, r |
| Q31031044 | Peritoneal Carcinomatosis from Colon Cancer: A Systematic Review of the Data for Cytoreduction and Intraperitoneal Chemotherapy |
| Q92617837 | Peritoneal sampling and histological assessment of therapeutic response in peritoneal metastasis: proposal of the Peritoneal Regression Grading Score (PRGS) |
| Q92618103 | Phase I/II study of oxaliplatin dose escalation via a laparoscopic approach using pressurized aerosol intraperitoneal chemotherapy (PIPOX trial) for nonresectable peritoneal metastases of digestive cancers (stomach, small bowel and colorectal): Rati |
| Q40242470 | Postoperative complications affect long-term outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis |
| Q91572974 | Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications |
| Q36758901 | Proactive Management for Gastric, Colorectal and Appendiceal Malignancies: Preventing Peritoneal Metastases with Hyperthermic Intraperitoneal Chemotherapy (HIPEC). |
| Q40251206 | Resectability of Peritoneal Carcinomatosis: Learnings from a Prospective Cohort of 533 Consecutive Patients Selected for Cytoreductive Surgery |
| Q38555902 | Role of aggressive surgery for peritoneal metastases |
| Q42324105 | Second-look surgery plus hyperthermic intraperitoneal chemotherapy for patients with colorectal cancer at high risk of peritoneal carcinomatosis: Does it really save lives? |
| Q97894909 | Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study |
| Q41682509 | Serious Postoperative Complications Affect Early Recurrence After Cytoreductive Surgery and HIPEC for Colorectal Peritoneal Carcinomatosis. |
| Q37698285 | Significance of urinary tract involvement in patients treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) |
| Q98281046 | Spectral photon-counting CT imaging of colorectal peritoneal metastases: initial experience in rats |
| Q90644219 | State of the Art - Rectal Cancer Surgery |
| Q30239825 | Strategies to prevent peritoneal carcinomatosis arising from colorectal cancer |
| Q51000263 | Survival and Prognostic Factors for Metachronous Peritoneal Metastasis in Patients with Colon Cancer. |
| Q60948065 | Systematic Review of Variations in Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Metastasis from Colorectal Cancer |
| Q36388283 | Systemic treatment of patients with metachronous peritoneal carcinomatosis of colorectal origin. |
| Q92462045 | The Current Status of Peritoneal Surface Oncology in Saudi Arabia |
| Q38882994 | The Initial Indian Experience with Cytoreductive Surgery and HIPEC in the Treatment of Peritoneal Metastases |
| Q39036955 | The Role of Neoadjuvant and Adjuvant Systemic Chemotherapy with Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Systematic Review |
| Q46596474 | The modified Glasgow prognostic score for early mortality in patients with synchronous peritoneal carcinomatosis from colorectal cancer |
| Q28067123 | Therapeutic options for peritoneal metastasis arising from colorectal cancer |
| Q88558404 | Treatment of colorectal peritoneal metastases requires multidisciplinary efforts |
| Q48102763 | Tumour spheres with inverted polarity drive the formation of peritoneal metastases in patients with hypermethylated colorectal carcinomas. |
| Q38988578 | Update on clinical trials in colorectal cancer peritoneal metastasis |
| Q38816501 | What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: A 25-year experience with 1,125 procedures |
Search more.